

Clinical Trial Protocol

Iranian Registry of Clinical Trials

04 Jun 2026

Effect off Microrelin (GnRH agonist) on uterine fibroma

Protocol summary

Summary

GnRH agonist are available as base, acetate, diacetate or ambonate. According to existing limitations in medical market in Iran it is supposed to focus on domestic production. No other study is done on the effect of this group of drugs on myoma size in Iran. This is a randomized clinical trial. In the age range of 18 to 50 years (all pre menopausal) patients candidate for hysteroscopic myoma resection are randomly divided into two groups of treatment and control (n= 30 for each group). Intervention is using microrelin in treatment group. Treatment is started in first 5 days of menstrual cycle by 3.7 mg depot ampule and is repeated for three consecutive cycles. Randomization is done by a nurse in clinic using random blocks. Serum levels of FSH, LH and estradiol are measured in weeks 0, 2 and 12 after beginning of the study. The size of myoma are measured using sonography before microrelin administration and before surgery. Feasibility of myoma resection, operation time recorded by the surgeon and the volume of fluid absorption during the operation are compared in two groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201408133950N3**

Registration date: **2014-11-22, 1393/09/01**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2014-11-22, 1393/09/01

Registrant information

Name

Mina Jafarabadei

Name of organization / entity

Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 6658 1616

Email address

jafarabadi@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for research of Tehran University of Medical Sciences

Expected recruitment start date

2014-04-04, 1393/01/15

Expected recruitment end date

2014-08-31, 1393/06/09

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect off Microrelin (GnRH agonist) on uterine fibroma

Public title

Effect of Microrelin on the size of uterus fibroma in patients undergoing hysteroscopic myoma resection

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria: Be a pre-menopausal woman between 18 and 50 years, have indication of surgical myomectomy due to any complain, Less than 2 myomas with the diameter of 2- 4 Cm which are totally intracavitary or have a myometrial expansion less than 50%, If of childbearing potential the subject must be practicing a non-hormonal method of contraception, BMI ≥ 18 and ≤ 40 . Exclusion Criteria: Indication of emergent surgery, history of or current uterine cervical, ovarian or

breast cancer, current endometrium atypical hyperplasia or adenocarcinoma, a known severe coagulation disorder, has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRH-agonist, Has a history of or known current osteoporosis, abnormal hepatic function at study entry, a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study, a current (within twelve months) problem with alcohol or drug abuse, is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

Age

From **18 years** old to **50 years** old

Gender

Female

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of research deputy, Tehran
University of Medical Sciences

Street address

Tehran University of Medical Sciences, Ghods
building, Keshavarz blvd., Tehran.

City

Tehran

Postal code**Approval date**

2014-07-20, 1393/04/29

Ethics committee reference number

92-03-39-23336

Health conditions studied**1****Description of health condition studied**

Leiomyoma of uterus

ICD-10 code

D25

ICD-10 code description

Leiomyoma of uterus

Primary outcomes**1****Description**

size of myoma

Timepoint

12 weeks after microrelin subscription

Method of measurement

sonography

Secondary outcomes**1****Description**

level of gonadotrophins and estrogen in serum

Timepoint

two and 12 weeks after microrelin subscription

Method of measurement

ELISA

2**Description**

Surgeon's satisfaction

Timepoint

end of operation

Method of measurement

Visual Assessment Score

3**Description**

Operation time

Timepoint

end of operation

Method of measurement

surjeon's announcement

4**Description**

Absorbed fluide volume

Timepoint

end of operation

Method of measurement

fluide gathered in suction subtracted from used fluide

Intervention groups

1

Description

intervention is using microrel in treatment group.
Treatment is started in first 5 days of menstrual cycle by 3.7 mg depot ampule and is repeated for three consecutive cycles.

Category

Treatment - Drugs

2

Description

Control Group: no treatment

Category

N/A

Recruitment centers

1

Recruitment center

Name of recruitment center

Reproductive Health Research Center, Tehran
University of medical Sciences

Full name of responsible person

Mina Jafarabadi

Street address

Reproductive Health Research Center, Emam Hospital
Complex, Keshavarz Blvd.,

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice Chancellor for Research of Tehran University of
Medical sciences

Full name of responsible person

Mrs Mostofi

Street address

Qods building, Keshavarz Blvd.,

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice Chancellor for Research of Tehran University of
Medical sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Reproductive Health research center

Full name of responsible person

Mina Jafarabadi

Position

M.D.

Other areas of specialty/work

Street address

Emam Hospital, Keshavarz Blvd., Tehran, Iran

City

Tehran

Postal code

Phone

+98 21 6658 1616

Fax

+98 21 6658 1658

Email

jafarabadi@tums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Reproductive Health Research Center

Full name of responsible person

Mina Jafarabadi

Position

M.D.

Other areas of specialty/work

Street address

Emam Hospital, Keshavarz Blvd.,

City

Tehran

Postal code

14194

Phone

+98 21 6658 1616

Fax

+98 21 6658 1658

Email

jafarabadi@tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Reproductive Health Research Center

Full name of responsible person

Fedyeh Haghollahi

Position

reseach expert

Other areas of specialty/work**Street address**

Reproductive Health Research Center, Imam Hospital,
Keshavarz Blvd.,

City

Tehran

Postal code

14194

Phone

+98 21 6658 1616

Fax

+98 21 6658 1658

Email

fedyeh_hagh@yahoo.com

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty